Its additional antioxidant and anti-inflammatory properties further enhance its therapeutic appeal, positioning Naringin as a promising alternative to conventional synthetic CDK1 inhibitors for ovarian cancer treatment. The gene discussed is CDK1; the disease is ovarian carcinoma.